*LIBTAYO was FDA approved in advanced CSCC in September 2018.1,4
Explore this video library featuring medical experts to learn more about LIBTAYO for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Watch videos discussing various topics including the efficacy and safety profile of LIBTAYO, clinical trial designs, and patient case studies.
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02760498. Updated January 26, 2021. Accessed March 24, 2021. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months. Poster presented at: European Association of Dermato Oncology Congress 2021 Virtual Scientific Meeting. 15-17 April 2021. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097. Updated June 25, 2020. Accessed January 19, 2021.